137 related articles for article (PubMed ID: 26198249)
1. Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi.
Walesch SK; Richter AM; Helmbold P; Dammann RH
Cancers (Basel); 2015 Jul; 7(3):1233-43. PubMed ID: 26198249
[TBL] [Abstract][Full Text] [Related]
2. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
[TBL] [Abstract][Full Text] [Related]
3. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma.
Shen Z; Cao B; Lin L; Zhou C; Ye D; Qiu S; Li Q; Cui X
Med Sci Monit; 2017 Jul; 23():3635-3640. PubMed ID: 28743857
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the tight junction gene CLDN11 by aberrant hypermethylation modulates tubulins polymerization and promotes cell migration in nasopharyngeal carcinoma.
Li HP; Peng CC; Wu CC; Chen CH; Shih MJ; Huang MY; Lai YR; Chen YL; Chen TW; Tang P; Chang YS; Chang KP; Hsu CL
J Exp Clin Cancer Res; 2018 May; 37(1):102. PubMed ID: 29747653
[TBL] [Abstract][Full Text] [Related]
6. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
7. Methylation status of the SOCS3 gene in human malignant melanomas.
Tokita T; Maesawa C; Kimura T; Kotani K; Takahashi K; Akasaka T; Masuda T
Int J Oncol; 2007 Mar; 30(3):689-94. PubMed ID: 17273770
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
10. Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors.
Watanabe T; Yachi K; Ohta T; Fukushima T; Yoshino A; Katayama Y; Shinojima Y; Terui T; Nagase H
Neurol Med Chir (Tokyo); 2010; 50(12):1062-9. PubMed ID: 21206179
[TBL] [Abstract][Full Text] [Related]
11. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Behrmann I; Wallner S; Komyod W; Heinrich PC; Schuierer M; Buettner R; Bosserhoff AK
Am J Pathol; 2003 Aug; 163(2):683-90. PubMed ID: 12875987
[TBL] [Abstract][Full Text] [Related]
12. Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function.
Arroyo Villora S; Castellanos Silva P; Zenz T; Kwon JS; Schlaudraff N; Nitaj D; Meckbach C; Dammann R; Richter AM
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397165
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Marini A; Mirmohammadsadegh A; Nambiar S; Gustrau A; Ruzicka T; Hengge UR
J Invest Dermatol; 2006 Feb; 126(2):422-31. PubMed ID: 16374457
[TBL] [Abstract][Full Text] [Related]
14. Methylated
Li J; Zhou C; Ni S; Wang S; Ni C; Yang P; Ye M
Oncotarget; 2017 Nov; 8(56):96249-96262. PubMed ID: 29221203
[TBL] [Abstract][Full Text] [Related]
15. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.
Rastetter M; Schagdarsurengin U; Lahtz C; Fiedler E; Marsch WCh; Dammann R; Helmbold P
Histol Histopathol; 2007 Sep; 22(9):1005-15. PubMed ID: 17523078
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
17. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.
Conway K; Edmiston SN; Parker JS; Kuan PF; Tsai YH; Groben PA; Zedek DC; Scott GA; Parrish EA; Hao H; Pearlstein MV; Frank JS; Carson CC; Wilkerson MD; Zhao X; Slater NA; Moschos SJ; Ollila DW; Thomas NE
J Invest Dermatol; 2019 Jun; 139(6):1349-1361. PubMed ID: 30529013
[TBL] [Abstract][Full Text] [Related]
19. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi.
Maitra A; Gazdar AF; Moore TO; Moore AY
Hum Pathol; 2002 Feb; 33(2):191-7. PubMed ID: 11957144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
